DNLI - Denali Therapeutics Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-0.75
|
Rev Est: $2.9M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.00
DETAILS
HIGH:
$40.00
LOW:
$25.00
MEDIAN:
$33.50
CONSENSUS:
$33.00
UPSIDE:
53.99%
Market Cap:
3.35B
Volume:
1,387,911
Avg Volume:
1,686,993
52 Week Range:
10.57-23.77
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.02
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
443
IPO Date:
2017-12-08
EPS (TTM):
-2.57
P/E Ratio:
-7.93
Revenue (TTM):
N/A
Total Assets:
1.37B
Total Debt:
48.71M
Cash & Equiv:
174.96M
Rev Growth (5Y):
-100.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-39.5%
Debt/Equity:
0.04
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-0.74 | $-0.76 | +2.6% | — | $2.9M | — |
| 2025-08-11 | $-0.72 | $-0.74 | +2.7% | — | $5.6M | — |
| 2025-05-06 | $-0.78 | $-0.71 | -9.9% | — | $3.0M | — |
| 2025-02-27 | $-0.67 | $-0.75 | +10.7% | — | $12.8M | — |
| 2024-11-06 | $-0.63 | $-0.60 | -5.0% | — | $11.6M | — |
| 2024-08-01 | $-0.59 | $-0.68 | +13.2% | — | $12.5M | — |
| 2024-05-07 | $-0.68 | $-0.67 | -1.5% | — | $14.0M | — |
| 2024-02-27 | $-0.86 | $-0.82 | -4.9% | $305.0M | $8.4M | +3548.8% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 330.53M | 108.46M | 48.66M | 335.66M | 26.68M | 129.16M | 0 | 0 | 0 |
| Net Income | (422.77M) | (145.22M) | (325.99M) | (290.58M) | 71.14M | (197.61M) | (36.24M) | (88.19M) | (86.65M) | (16.79M) |
| EPS | -2.57 | -1.06 | -2.60 | -2.39 | 0.65 | -2.07 | -0.39 | -5.89 | -13.49 | -5.58 |
| Total Assets | 1.37B | 1.15B | 1.46B | 1.40B | 1.60B | 553.23M | 661.98M | 486.72M | 271.07M | 36.68M |
| Total Debt | 48.71M | 52.24M | 60.35M | 64.01M | 68.86M | 72.53M | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 174.96M | 127.11M | 218.04M | 293.48M | 507.14M | 79.45M | 77.12M | 218.38M | 39.85M | 30.74M |
| Operating Cash Flow | (347.69M) | (357.99M) | (244.72M) | (211.39M) | 416.15M | (151.58M) | 50.12M | (76.64M) | (72.36M) | (15.05M) |
| Free Cash Flow | (363.61M) | (370.93M) | (262.55M) | (219.89M) | 413.06M | (169.50M) | 46.72M | (79.51M) | (78.49M) | (18.11M) |
| FCF per Share | -2.21 | -2.70 | -2.09 | -1.81 | 3.79 | -1.77 | 0.50 | -5.31 | -12.22 | -6.03 |
| Book Value | 1.23B | 1.03B | 1.04B | 962.29M | 1.15B | 394.89M | 546.85M | 465.80M | 254.52M | (15.63M) |
| Cash & ST Investments | 832.33M | 1.03B | 1.34B | 865.41M | 1.47B | 415.36M | 464.30M | 406.23M | 178.33M | 30.74M |
| ROC Equity | -0.34 | -0.14 | -0.31 | -0.30 | 0.06 | -0.50 | -0.07 | -0.19 | -0.34 | N/A |